Oncology

News

EMERALD-3 suggests a triplet regimen based on AstraZeneca's Imfinzi and Imjudo could be practice-changing as a frontline hepatocellular carcinoma.

News

The SARCO41 study suggests Lilly's Verzenio could become the first targeted therapy for rare, aggressive tumour dedifferentiated liposarcoma.

News

Millions of women with a breast cancer diagnosis could safely avoid chemotherapy that would not be effective, thanks to a genomics test.

News

Revolution Medicines' pan-RAS(on) inhibitor daraxonrasib has delivered an unprecedented result in pancreatic cancer.

News

Akeso and Summit's PD-1xVEGF drug ivonescimab has improved survival in the HARMONi-6 trial, throwing down a marker for the emerging class.

News

Lilly looks set to extend the reach of RET inhibitor Retevmo in RET+ lung cancer, as the LIBRETTO-432 trial shows its value as adjuvant therapy.